123 related articles for article (PubMed ID: 29170500)
1. White matter disease: Targeted aspartoacylase gene therapy reverts Canavan disease.
Starling S
Nat Rev Neurol; 2018 Jan; 14(1):4. PubMed ID: 29170500
[No Abstract] [Full Text] [Related]
2. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
[TBL] [Abstract][Full Text] [Related]
3. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ
Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900
[TBL] [Abstract][Full Text] [Related]
4. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain.
Janson C; McPhee S; Bilaniuk L; Haselgrove J; Testaiuti M; Freese A; Wang DJ; Shera D; Hurh P; Rupin J; Saslow E; Goldfarb O; Goldberg M; Larijani G; Sharrar W; Liouterman L; Camp A; Kolodny E; Samulski J; Leone P
Hum Gene Ther; 2002 Jul; 13(11):1391-412. PubMed ID: 12162821
[TBL] [Abstract][Full Text] [Related]
5. Redirecting
Gessler DJ; Li D; Xu H; Su Q; Sanmiguel J; Tuncer S; Moore C; King J; Matalon R; Gao G
JCI Insight; 2017 Feb; 2(3):e90807. PubMed ID: 28194442
[TBL] [Abstract][Full Text] [Related]
6. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
[TBL] [Abstract][Full Text] [Related]
7. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease.
Leone P; Janson CG; Bilaniuk L; Wang Z; Sorgi F; Huang L; Matalon R; Kaul R; Zeng Z; Freese A; McPhee SW; Mee E; During MJ
Ann Neurol; 2000 Jul; 48(1):27-38. PubMed ID: 10894213
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for Canavan's disease takes a step forward.
Ahmed SS; Gao G
Mol Ther; 2013 Mar; 21(3):505-6. PubMed ID: 23449107
[No Abstract] [Full Text] [Related]
9. rAAV Gene Therapy in a Canavan's Disease Mouse Model Reveals Immune Impairments and an Extended Pathology Beyond the Central Nervous System.
Ahmed SS; Schattgen SA; Frakes AE; Sikoglu EM; Su Q; Li J; Hampton TG; Denninger AR; Kirschner DA; Kaspar B; Matalon R; Gao G
Mol Ther; 2016 Jun; 24(6):1030-1041. PubMed ID: 27039844
[TBL] [Abstract][Full Text] [Related]
10. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
[TBL] [Abstract][Full Text] [Related]
11. Canavan disease: studies on the knockout mouse.
Matalon R; Michals-Matalon K; Surendran S; Tyring SK
Adv Exp Med Biol; 2006; 576():77-93; discussion 361-3. PubMed ID: 16802706
[TBL] [Abstract][Full Text] [Related]
12. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease.
Kaul R; Gao GP; Balamurugan K; Matalon R
Nat Genet; 1993 Oct; 5(2):118-23. PubMed ID: 8252036
[TBL] [Abstract][Full Text] [Related]
13. Novel mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
Unalp A; Altiok E; Uran N; Oztürk A; Yüksel S
J Trop Pediatr; 2008 Jun; 54(3):208-10. PubMed ID: 17999961
[TBL] [Abstract][Full Text] [Related]
14. Spongy degeneration of the brain, Canavan disease: biochemical and molecular findings.
Matalon RM; Michals-Matalon K
Front Biosci; 2000 Mar; 5():D307-11. PubMed ID: 10704428
[TBL] [Abstract][Full Text] [Related]
15. A novel aspartoacylase (ASPA) gene mutation in Canavan disease.
Durmaz AA; Akin H; Onay H; Vahabi A; Ozkinay F
Fetal Pediatr Pathol; 2012 Aug; 31(4):236-9. PubMed ID: 22468686
[TBL] [Abstract][Full Text] [Related]
16. Mouse neural progenitor cells differentiate into oligodendrocytes in the brain of a knockout mouse model of Canavan disease.
Surendran S; Shihabuddin LS; Clarke J; Taksir TV; Stewart GR; Parsons G; Yang W; Tyring SK; Michals-Matalon K; Matalon R
Brain Res Dev Brain Res; 2004 Oct; 153(1):19-27. PubMed ID: 15464214
[TBL] [Abstract][Full Text] [Related]
17. Biochemistry and molecular biology of Canavan disease.
Matalon R; Michals-Matalon K
Neurochem Res; 1999 Apr; 24(4):507-13. PubMed ID: 10227683
[TBL] [Abstract][Full Text] [Related]
18. Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan disease.
Zano S; Malik R; Szucs S; Matalon R; Viola RE
Mol Genet Metab; 2011 Feb; 102(2):176-80. PubMed ID: 21095151
[TBL] [Abstract][Full Text] [Related]
19. A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice.
Ahmed SS; Li H; Cao C; Sikoglu EM; Denninger AR; Su Q; Eaton S; Liso Navarro AA; Xie J; Szucs S; Zhang H; Moore C; Kirschner DA; Seyfried TN; Flotte TR; Matalon R; Gao G
Mol Ther; 2013 Dec; 21(12):2136-47. PubMed ID: 23817205
[TBL] [Abstract][Full Text] [Related]
20. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
Eke GH; Iscan A; Cece H; Calik M
Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
